Kripthonite Therapeutics ApS: Financial statements 2024
CVR: 43770209
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Kripthonite Therapeutics ApS (CVR 43770209) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 125,449 and a net result of DKK -32 compared with DKK -5,407 the year before. That is a decrease of 76.8% compared with the year before. Equity in the 2024 report amounted to DKK 34,561. The solvency ratio was 20.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 125,449
- Profit/Loss
- DKK -32
- Equity
- DKK 34,561
- Total Assets
- DKK 168,503
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 125 t. | -32 | 35 t. | 1 |
| 2023 | - | 542 t. | -5 t. | 35 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Kripthonite Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 541,641, and the net result was DKK -5,407.
About Kripthonite Therapeutics ApS
Kripthonite Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Stenvang. The board consists of Søren Bregenholt Frederiksen (chair), Erik Vinther, Kristian Mark Jacobsen and Per Hjerrild. The company's owners include Marigold Innovation ApS, Thomas B. Poulsen Holding ApS and Hjerrild Chemistry Consulting ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK -3,512,912 and a net result of DKK -3,936,274 compared with DKK -32 the year before. Equity in the 2025 report amounted to DKK 4,598,287.